Introduction of Performance-Linked Restricted Stock Compensation
First written in FY2016. 15 of 24 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026-H1.
77 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「24 March 2026 (Note) Paid third-party allotment as restricted stock-based compensation」
The Company allotted 84,855 shares to 13 people as restricted stock-based compensation, increasing stated capital and capital surplus by ¥21 million each. - FY2025-H1AdvancedAnnual report
「25 March 2025 (Note) Paid third-party allotment as restricted stock-based compensation」
The Company allotted 114,734 shares to 15 people as restricted stock-based compensation, increasing stated capital and capital surplus by ¥24 million each. - FY2024RestatedAnnual report
「For each fiscal year, consolidated net sales, EBITDA margin and return on equity (ROE) are used as performance metrics for performance-linked compensation, and points are awarded according to the directors' positions and target achievement rates, with 1 share awarded per point.」
Consolidated net sales, EBITDA margin and ROE continued to be used as performance-linked metrics for the BIP trust. The results for the current period were disclosed as net sales of ¥57,993 million, an EBITDA margin of 8.8% and ROE of negative 9.4%. - FY2024-Q2Disclosure of shares held by the BIP trust for executive compensationAnnual report
「This includes 664,974 shares of the Company held by the BIP trust for executive compensation, representing 6,649 voting rights.」
The 664,974 shares held by the BIP trust for executive compensation were disclosed in the voting rights information. - FY2024-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 28 February 2024, the Company resolved to issue new shares as restricted stock-based compensation. Following the issuance of these new shares dated 26 March 2024, the total number of issued shares increased to 98,328, and both stated capital and capital surplus increased by ¥23.697 million.」
The Company resolved to issue 98,328 new shares as restricted stock-based compensation and carried out the issuance dated 26 March 2024. - FY2023-Q2AdvancedAnnual report
「Following the issuance of these new shares dated 20 March 2023, the total number of issued shares increased to 40,884,504, and both stated capital and capital surplus increased by ¥23.997 million.」
The Company issued 112,138 shares to 13 people dated 20 March 2023 as restricted stock-based compensation, increasing stated capital and capital surplus by ¥23.997 million each. - FY2023-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 22 February 2023, the Company resolved to issue new shares as restricted stock-based compensation. Following the issuance of these new shares dated 20 March 2023, the total number of issued shares increased to 112,138, and both stated capital and capital surplus increased by ¥23.997 million.」
The Company issued 112,138 new shares dated 20 March 2023 as restricted stock-based compensation. - FY2022AdvancedAnnual report
「For each fiscal year, consolidated net sales, EBITDA margin and return on equity (ROE) are used as performance metrics for performance-linked compensation, and points are awarded according to the directors' positions and target achievement rates, with 1 share awarded per point.」
The performance metrics for the BIP trust were specified as consolidated net sales, EBITDA margin and ROE, with shares awarded according to the target achievement rate. - FY2022-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 25 February 2022, a resolution was passed to issue new shares as restricted stock compensation. The issue of these new shares dated 23 March 2022 increased the total number of issued shares by 142,279 and increased both share capital and the capital reserve by ¥29,096 thousand.」
The issue of 142,279 new shares as restricted stock compensation was approved and carried out on 23 March 2022. - FY2021-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 24 February 2021, a resolution was passed to issue new shares as restricted stock compensation. The issue of these new shares dated 22 March 2021 increased the total number of issued shares by 79,348 and increased both share capital and the capital reserve by ¥24,597 thousand.」
The issue of 79,348 new shares as restricted stock compensation was approved, and the shares were issued on 22 March 2021. - FY2020AdvancedAnnual report
「At the 80th Annual General Meeting of Shareholders held on 26 February 2020 and the 81st Annual General Meeting of Shareholders held on 24 February 2021, resolutions were passed to continue and partially revise the trust-based share compensation scheme.」
The continuation and partial revision of the BIP trust scheme were approved at the general meeting of shareholders, and the annual share caps were disclosed as 360 thousand for System I and 530 thousand for System II. The Company also indicated that, beginning in the next fiscal year, it plans to use ROE and other metrics instead of ROIC. - FY2020-Q3Decrease in shares held by the BIP trustAnnual report
「The total dividends approved by the Board of Directors on 10 July 2020 include ¥6,249 thousand in dividends on the Company's 636 thousand shares held by the executive compensation BIP trust and 255 thousand shares held by the employee stock ownership ESOP trust.」
The executive compensation BIP trust held 636 thousand shares, down from 687 thousand shares disclosed previously. - FY2020-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 26 February 2020, a resolution was passed to issue new shares as restricted stock compensation. The issue of these new shares dated 23 March 2020 increased the total number of issued shares by 93,781 and increased both share capital and the capital reserve by ¥23,398 thousand.」
The issue of 93,781 new shares as restricted stock compensation was approved, and the shares were issued on 23 March 2020. - FY2019AdvancedAnnual report
「At a meeting of the Board of Directors held on 22 January 2020, the Company resolved to continue and partially revise System I, and the proposal concerning this matter was approved at the 80th Annual General Meeting of Shareholders held on 26 February 2020. System I: the annual cap on the number of shares is 360 thousand, of which 300 thousand are for the Company's directors.」
The continuation and partial revision of the BIP trust scheme progressed through approval by the Board of Directors and the annual general meeting of shareholders, and the annual share cap of 360 thousand was also disclosed. - FY2019-Q3Decrease in shares held by the BIP trustAnnual report
「The total dividends approved by the Board of Directors on 11 July 2019 include ¥6,263 thousand in dividends on the Company's 687 thousand shares held by the executive compensation BIP trust and 356 thousand shares held by the employee stock ownership ESOP trust.」
The executive compensation BIP trust held 687 thousand shares, down from 764 thousand shares disclosed previously. - FY2019-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 22 February 2019, a resolution was passed to issue new shares as restricted stock compensation. The issue of these new shares dated 18 March 2019 increased the total number of issued shares by 127,269 and increased both share capital and the capital reserve by ¥26,599 thousand.」
The issue of 127,269 new shares as restricted stock compensation was approved, and the shares were issued on 18 March 2019. - FY2018-Q3RestatedAnnual report
「The total dividends approved by the Board of Directors on 12 July 2018 include ¥6,077 thousand in dividends on the Company's 764 thousand shares held by the executive compensation BIP trust and 451 thousand shares held by the employee stock ownership ESOP trust.」
The operation of the executive compensation BIP trust and its holdings of 764 thousand shares continued to be disclosed. - FY2018-Q2RestatedAnnual report
「*The total dividends include ¥6,077 thousand in dividends on the Company's 764 thousand shares held by the executive compensation BIP trust and 451 thousand shares held by the employee stock ownership ESOP trust.」
The operation of the executive compensation BIP trust and its holdings of 764 thousand shares continued to be disclosed. - FY2018-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 23 February 2018, a resolution was passed to issue new shares as restricted stock compensation. The issue of these new shares dated 20 March 2018 is expected to increase the total number of issued shares by 151,409 and increase both share capital and the capital reserve by ¥32,098 thousand.」
The issue of 151,409 new shares as restricted stock compensation was approved, with the issue scheduled for 20 March. - FY2017RestatedAnnual report
「The Company and the subsidiaries covered by the scheme introduced this scheme for the eligible directors. For System I, the objectives are to clarify the linkage between eligible directors' compensation and the performance of our Group and shareholder value, and to heighten awareness of contributing to improved performance over the medium to long term and increased corporate value. For System II, the objectives are to provide eligible directors with incentives to achieve sustained growth in our Group's corporate value and to promote greater value sharing with shareholders.」
The executive compensation BIP trust and restricted stock compensation are operated to link compensation with performance and shareholder value and to enhance corporate value. - FY2017-Q3RestatedAnnual report
「Beginning in the second quarter of the current consolidated fiscal year, the Company introduced an executive compensation BIP trust as a trust-based share compensation scheme for directors of the Company and its 2 subsidiaries, Iwaki Pharmaceutical Co., Ltd. and Meltax Co., Ltd., excluding outside directors and non-residents of Japan.」
The introduction and operation of the executive compensation BIP trust continued to be disclosed in the third-quarter report, and the shares remaining in the trust amounted to 767 thousand. - FY2017-Q2AdvancedAnnual report
「Beginning in the second quarter of the current consolidated fiscal year, the Company introduced an executive compensation BIP trust as a trust-based share compensation scheme for directors of the Company and its 2 subsidiaries, Iwaki Pharmaceutical Co., Ltd. and Meltax Co., Ltd., excluding outside directors and non-residents of Japan.」
The executive compensation BIP trust, whose introduction had previously been approved, was implemented from the second quarter, and 432 thousand shares held by the trust were also disclosed. - FY2017-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 24 February 2017, a resolution was passed to issue new shares as restricted stock compensation. The issue of these new shares dated 22 March 2017 increased the total number of issued shares to 209,643 and increased both share capital and the capital reserve by ¥32,599 thousand.」
The Company issued 209,643 new shares under the previously approved restricted stock compensation plan. - FY2016First statedAnnual report
「System I is a scheme under which the Company will deliver its shares and other consideration as director compensation based on performance achievement and position for the 3 fiscal years from the fiscal year ending 30 November 2017 through the fiscal year ending 30 November 2019.」
The annual general meeting of shareholders approved the introduction of a BIP trust and restricted stock compensation, under a scheme linked to performance achievement and other factors over 3 fiscal years. The ¥280 million cap on trust funding and the issuance cap for restricted stock were also disclosed.